Rubius Therapeutics, Inc. (NASDAQ:RUBY) is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, RUBY is expected to report 2Q20 loss of $ 0.5 per share.
For the full year, analysts anticipate loss of $ 2.01 per share bottom line.
Previous Quarter Performance
Rubius Therapeutics, Inc. unveiled loss for the first quarter of $ 0.60 per share, from the revenue of . Wall street analysts are predicting, loss of $ 0.55 per share The bottom line results missed street analysts by $ 0.05 or 9.09 percent, at the same time, top line results analysts by $ 0.69 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of RUBY was $ 5.18, representing a 54.63 % increase from the 52 week low of $ 3.35 and a 64.13 % decrease over the 52 week high of $ 14.44.
The company has a market capital of $ 416.87 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”RUBY” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
